255 related articles for article (PubMed ID: 26808368)
41. Prevention of mercaptopurine-induced hypoglycemia using allopurinol to reduce methylated thiopurine metabolites.
Miller MB; Brackett J; Schafer ES; Rau RE
Pediatr Blood Cancer; 2019 Apr; 66(4):e27577. PubMed ID: 30548777
[TBL] [Abstract][Full Text] [Related]
42. Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia.
Albayrak M; Konyssova U; Kaya Z; Gursel T; Guntekin S; Percin EF; Kocak U
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1155-9. PubMed ID: 21400026
[TBL] [Abstract][Full Text] [Related]
43. Continuous glucose monitoring: a valuable monitoring tool for management of hypoglycemia during chemotherapy for acute lymphoblastic leukemia.
Visavachaipan N; Aledo A; Franklin BH; Brar PC
Diabetes Technol Ther; 2013 Jan; 15(1):97-100. PubMed ID: 23145966
[TBL] [Abstract][Full Text] [Related]
44. Thiopurine S-methyltransferase (TPMT) gene polymorphism in Brazilian children with acute lymphoblastic leukemia: association with clinical and laboratory data.
Silva MR; de Oliveira BM; Viana MB; Murao M; Romanha AJ
Ther Drug Monit; 2008 Dec; 30(6):700-4. PubMed ID: 19057372
[TBL] [Abstract][Full Text] [Related]
45. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
[TBL] [Abstract][Full Text] [Related]
46. Cytomegalovirus retinitis as an adverse immunological effect of pulses of vincristine and dexamethasone in maintenance therapy for childhood acute lymphoblastic leukemia.
Moritake H; Kamimura S; Kojima H; Shimonodan H; Harada M; Sugimoto T; Nao-I N; Nunoi H
Pediatr Blood Cancer; 2013 Feb; 60(2):329-31. PubMed ID: 22976937
[TBL] [Abstract][Full Text] [Related]
47. Erythrocyte concentrations of metabolites or cumulative doses of 6-mercaptopurine and methotrexate do not predict liver changes in children treated for acute lymphoblastic leukemia.
Halonen P; Mattila J; Mäkipernaa A; Ruuska T; Schmiegelow K
Pediatr Blood Cancer; 2006 Jun; 46(7):762-6. PubMed ID: 16395677
[TBL] [Abstract][Full Text] [Related]
48. Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature.
Witte TN; Ginsberg AL
Can J Gastroenterol; 2008 Feb; 22(2):181-5. PubMed ID: 18299738
[TBL] [Abstract][Full Text] [Related]
49. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M
Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286
[TBL] [Abstract][Full Text] [Related]
50. [6-mercaptopurine-related hand-foot syndrome in a four-year-old child].
Giacchero D; Monpoux F; Chiavérini C; Lacour JP
Ann Dermatol Venereol; 2008; 135(8-9):580-3. PubMed ID: 18789293
[TBL] [Abstract][Full Text] [Related]
51. Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens.
Innocenti F; Danesi R; Bocci G; Fogli S; Di Paolo A; Del Tacca M
Cancer Chemother Pharmacol; 1999; 43(2):133-40. PubMed ID: 9923818
[TBL] [Abstract][Full Text] [Related]
52. Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia.
Chrzanowska M; Kolecki P; Duczmal-Cichocka B; Fiet J
Eur J Pharm Sci; 1999 Aug; 8(4):329-34. PubMed ID: 10425383
[TBL] [Abstract][Full Text] [Related]
53. Serendipity-methotrexate and 6-mercaptopurine for continuation therapy for patients with acute lymphoblastic leukemia: the leukemic stem cell and beyond?
Kamen BA
J Pediatr Hematol Oncol; 2009 Jun; 31(6):383-4. PubMed ID: 19648785
[No Abstract] [Full Text] [Related]
54. A novel 6-mercaptopurine oral liquid formulation for pediatric acute lymphoblastic leukemia patients - results of a randomized clinical trial.
Hanff LM; Mathot RA; Smeets O; Postma DJ; Ramnarain S; Vermes A; Pieters R; Zwaan CM
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):653-62. PubMed ID: 24800919
[TBL] [Abstract][Full Text] [Related]
55. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
[TBL] [Abstract][Full Text] [Related]
56. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
[TBL] [Abstract][Full Text] [Related]
57. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.
Harms DO; Göbel U; Spaar HJ; Graubner UB; Jorch N; Gutjahr P; Janka-Schaub GE;
Blood; 2003 Oct; 102(8):2736-40. PubMed ID: 12843002
[TBL] [Abstract][Full Text] [Related]
58. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
Fakhoury M; Andreu-Gallien J; Mahr A; Medard Y; Azougagh S; Vilmer E; Jacqz-Aigrain E
J Clin Pharm Ther; 2007 Dec; 32(6):633-9. PubMed ID: 18021342
[TBL] [Abstract][Full Text] [Related]
59. Acral Skin Rash Caused by Altered Mercaptopurine Metabolism in Maintenance Therapy for B-Cell Acute Lymphoblastic Leukemia.
Newcome J; Geib KB; Thompson P; Gold S; Alexander TB
J Pediatr Hematol Oncol; 2022 Oct; 44(7):398-401. PubMed ID: 35180762
[TBL] [Abstract][Full Text] [Related]
60. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.
Adam de Beaumais T; Jacqz-Aigrain E
Eur J Clin Pharmacol; 2012 Sep; 68(9):1233-42. PubMed ID: 22421815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
